Eckert & Ziegler boosts early phase offering with Vitalea Science takeover

- Last updated on GMT

Isotope tech firm Eckert & Ziegler buys bioanalytical CRO Vitalea
Isotope technology firm Eckert & Ziegler has acquired bioanalytical CRO Vitalea Science.

The deal - terms of which were not disclosed - adds Vitalea’s range of accelerator mass spectrometry (AMS) technologies and preclinical and early phase clinical services to Eckert & Ziegler’s offering.

Frank Yeager, president and CEO of Eckert & Ziegler Isotope Products, said: "Vitalea is a unique company with a very unique capability built around the BioMICADAS device, which is the state-of-the-art in AMS technology. We believe that this capability will both allow Eckert & Ziegler to add value to our existing customer base and expand our area of expertise in new markets."

This was echoed by Bob Bethem, president and CEO at Vitalea Science, who said that: “The acquisition of Vitalea Science by Eckert & Ziegler helps to provide the commercial strength of EZAG to the technical prowess of Vitalea."

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers